SCOPUS 정보 검색 플랫폼

Journal of Nutrition

Volumn 136, Issue 10, 2006, Pages

PSA: A biomarker for disease. A biomarker for clinical trials. How useful is it?

(1) Thompson, Ian M a

a Mays Cancer Center at UT Health San Antonio (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN SPECIFICITY; BODY MASS; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; HUMAN; MORBIDITY; OBESITY; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 33749484663 PISSN: 00223166 EISSN: 15416100 Source Type: Journal
DOI: 10.1093/jn/136.10.2704s Document Type: Conference Paper

Times cited : (12)

References (3)

1
- 2442715038
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter
- Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004;350:2239-46.
- (2004) N Engl J Med , vol.350 , pp. 2239-2246
- Thompson, I.M.¹ Pauler, D.K.² Goodman, P.J.³ Tangen, C.M.⁴ Lucia, M.S.⁵ Parnes, H.L.⁶ Minasian, L.M.⁷ Ford, L.G.⁸ Lippman, S.M.⁹

2
- 21444447966
- Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
- Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66-70.
- (2005) JAMA , vol.294 , pp. 66-70
- Thompson, I.M.¹ Ankerst, D.P.² Chi, C.³ Lucia, M.S.⁴ Goodman, P.J.⁵ Crowley, J.J.⁶ Parnes, H.L.⁷ Coltman Jr., C.A.⁸

3
- 0032146642
- Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study
- Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998;52:195-202.
- (1998) Urology , vol.52 , pp. 195-202
- Andriole, G.L.¹ Guess, H.A.² Epstein, J.I.³ Wise, H.⁴ Kadmon, D.⁵ Crawford, E.D.⁶ Hudson, P.⁷ Jackson, C.L.⁸ Romas, N.A.⁹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.